welcome to DuchenneXchange- a positively charged Duchenne muscular dystrophy community.
- join today!
Plus Epicatechin Duchenne Muscular Dystrophy in Non-ambulatory Adolescents
study id #: NCT02964377
condition: Duchenne Muscular Dystrophy
This single center open-label pilot study will enroll 15 non-ambulatory children with Duchenne muscular dystrophy at least 8 years of age and who demonstrate pre-clinical cardiomyopathy (defined as a cardiac ejection fraction >55% with abnormal LV strain by cardiac MRI). They will receive (+)-epicatechin at one of three doses during an 8-week dose-ranging study with assessments at baseline, 2 Weeks, 4weeks, and 8 weeks. The study will determine optimal dosing for future cardiac efficacy studies based on serum / plasma biomarker response using follistatin: myostatin ratio, nitrite/nitrate ratio, cardiac troponins and cardiac BNP. Secondary endpoints will include additional biomarker assessments by SOMAscanTM, cardiac functional evaluations by cardiac MRI (LV strain), and echocardiogram (LV strain by speckle tracking) and measures of strength, range of motion and mobility, and clinical safety assessments. Results of secondary endpoint analysis will be used to refine design of subsequent clinical trials powered to detect changes in clinical outcomes.
intervention: (+)- Epicatechin
mechanism of action: Antioxidant to reduce inflammation
last updated: January 21, 2019
start date: November 2016
estimated completion: July 2018
phase of development: Phase 1/Phase 2
size / enrollment: 15
- Pharmacokinetics Outcome: (+)-epicatechin trough (Cmin) serum concentration [Time Frame: Baseline, Week 2, Week 4, Week 8]
Pharmacokinetic evaluation for dose-response evaluation.
- Pharmacokinetics Outcome: (+)-epicatechin peak (Cmax) serum concentration [Time Frame: Baseline, Week 2, Week 4, Week 8]
Pharmacokinetic evaluation for dose-response evaluation.
- Laboratory Outcome: Change in plasma follistatin:myostatin ratio [Time Frame: Change from Baseline to Week 4 and Week 8]
Evaluation of follistatin:myostatin ratio from plasma samples.
- Clinical Outcome: Percent change in cardiac ejection fraction and shortening fraction by MRI [Time Frame: Change from Baseline to Week 4 and Week 8]
Evaluation of change in cardiac volume and performance.
- Safety: Clinical laboratory blood chemistry evaluation [Time Frame: Screening, Baseline, Week 2, Week 4, Week 8]
Evaluation of routine safety laboratory blood chemistry assessments for clinical safety monitoring.
- Safety: Complete blood count evaluation [Time Frame: Screening, Baseline, Week 2, Week 4, Week 8]
Evaluation of routine complete blood count for clinical safety monitoring.
- Safety: Urinalysis [Time Frame: Screening, Baseline, Week 2, Week 4, Week 8] Evaluation of routine urinalysis for clinical safety monitoring.
- Clinical Outcome: Percent change in normalized upper extremity reachable surface area. [Time Frame: Change from Baseline to Week 4 and Week 8]
Quantitative upper extremity reachable workspace will be assess using the XBox Kinect system.
- Clinical Outcome: Percent change in Performance of the Upper Limb Assessment score. [Time Frame: Change from Baseline to Week 4 and Week 8]
The standardized Performance of Upper Limb (PUL) measure will be assessed at baseline and after 8 weeks.
- Clinical Outcome: Percent change in 6-minute cycle test maximal attained revolutions. [Time Frame: Change from Baseline to Week 4 and Week 8]
The upper extremity 6-minute cycle test (work output and revolutions per 6-minutes) will be assessed as a measure of endurance.
- Person-Reported Outcome: Percent change in POSNA Pediatric Outcomes Data Collection Instrument (PODCI) quality of life instrument score [Time Frame: Change from Baseline to Week 4 and Week 8]
The Total, Transfer / basic Mobility, and upper limb health-related Quality of Life will be assed using the PODCI / POSNA
- Person-Reported Outcome: Percent change in Person-Reported Outcome Measure Upper Limb (PROM-UL) functional capacity score. [Time Frame: Change from Baseline to Week 4 and Week 8] Upper limb self-reported function will be assessed using the Person-Reported Outcome Measure Upper Limb (PROM-UL) functional capacity score.
• Age 8 years to 17 years
• Non-Ambulatory (unable to complete 10m run/walk under 10s)
• Diagnosis of DMD confirmed by at least one the following:
Dystrophin immunofluorescence and/or immunoblot showing complete dystrophin
deficiency, and clinical picture consistent with typical DMD, or
Gene deletions test positive (missing one or more exons) of the dystrophin gene, where reading frame can be predicted as 'out-of-frame', and clinical picture consistent with typical DMD, or
Complete dystrophin gene sequencing showing an alteration (point mutation, duplication, or other mutation resulting in a stop codon mutation) that can be definitely associated with DMD, with a typical clinical picture of DMD, or
Positive family history of DMD confirmed by one of the criteria listed above in a sibling or maternal uncle, and clinical picture typical of DMD.
• Cardiac ejection fraction >55% on echocardiogram
• Use of nutritional, herbal and antioxidant supplements taken with the intent of maintaining or improving skeletal muscle strength or functional mobility has been discontinued at least 4 weeks prior to screening (daily multivitamin use is acceptable).
• Glucocorticoid therapy, if used, must have a stable weight-based dose for at least 3 months prior to enrollment
• Cardiac therapy, if used, includes prophylactic ACE inhibitors, aldosterone receptor antagonists (e.g. spironolactone, eplerenone, etc.), and/or beta-blocker therapy, and must be stable for 3 months prior to enrollment.
• Hematology profile within normal range.
• Baseline laboratory safety chemistry profile within typical range for DMD (elevated ALT / AST acceptable in the absence of elevated GGT, elevated CK acceptable).
• Inability to complete cardiac or strength, range of motion and mobility assessments per protocol
• Current enrollment in another treatment clinical trial.
• History of significant concomitant illness or significant impairment of renal or hepatic function.
• Use of regular daily aspirin or other medication with antiplatelet effects within 3 weeks of first dose of study medication.
• Cardiac symptoms that, in the opinion of the investigator, may be suggestive of imminent moderate to severe cardiac events, irrespective of LVEF.
A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambu...The purpose of this study is investigate...
Clinical Intramuscular Gene Transfer of rAAV1.CMV.huFollistatin344 Trial to Patients With Duchenne Muscular Dystroph...The proposed clinical trial is an outgro...
Clinical Trial to Evaluate the Efficacy, Safety, and Tolerability of RO7239361 in Ambulatory Boys With Duchenne Musc...This is a multi-center, randomized, doub...
Catabasis Pharmaceuticals Announces Publication Of Phase 1 Clinical Results Of Edasalonexent (CAT-1004) In Duchenne ...Catabasis Pharmaceuticals, Inc., a clini...
Phase IIa trial in Duchenne muscular dystrophy shows vamorolone is a first-in-class dissociative steroidal anti-infl...We report a first-in-patient study of va...
Phase 1 Study of Edasalonexent (CAT-1004), an Oral NF-κB Inhibitor, in Pediatric Patients with Duchenne Muscular Dy...Background: Edasalonexent is an orally ...
Study of Ataluren in >=2 to <5 Year-Old Males With Duchenne Muscular DystrophyThis is a Phase 2, multiple-dose, open-l...
Potential DMD Therapy Vamorolone Shows Positive Effects in Phase 2a Trial, Study ReportsVamorolone, a Duchenne muscular dystroph...
Sarepta Therapeutics to Provide Update on Duchenne Muscular Dystrophy Gene Therapy ProgramSarepta Therapeutics, Inc., the leader i...